{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:03:36Z","timestamp":1784765016015,"version":"3.55.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cld.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:26:34Z","timestamp":1779276394000},"page":"571-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Scientific Basis of Cholestatic Liver Disease and Its Symptom Complex"],"prefix":"10.1016","volume":"30","author":[{"given":"Henry H.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cld.2026.04.001_bib1","doi-asserted-by":"crossref","first-page":"ITC129","DOI":"10.7326\/AITC202109210","article-title":"Care of the patient with abnormal liver test results","volume":"174","author":"Tran","year":"2021","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/jgh.13738","article-title":"Diagnostic considerations for cholestatic liver disease","volume":"32","author":"Pollock","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib3","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.001_bib5","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48431","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","volume":"8","author":"Yu","year":"2019","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Journal of the American College of Gastroenterology | ACG"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.20276","article-title":"Quality of life in patients with primary biliary cirrhosis","volume":"40","author":"Poupon","year":"2004","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2026.04.001_bib9","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/liv.15982","article-title":"Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat","volume":"44","author":"Karatza","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.001_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.903360","article-title":"The covert surge: Murine bile acid levels are associated with pruritus in pediatric autoimmune sclerosing cholangitis","volume":"10","author":"Meinel","year":"2022","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"Kremer","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12876-019-1092-z","article-title":"Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis","volume":"19","author":"Fujino","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2026.04.001_bib14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/metabo12100952","article-title":"Serum bile acid profiling and mixed model analysis reveal biomarkers associated with pruritus reduction in Maralixibat-Treated patients with BSEP deficiency","volume":"12","author":"Zhao","year":"2022","journal-title":"Metabolites"},{"issue":"21","key":"10.1016\/j.cld.2026.04.001_bib15","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.cld.2026.04.001_bib16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpdd.34","article-title":"Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes","volume":"2","author":"Hodge","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129866","article-title":"Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling","volume":"10","author":"Cipriani","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cld.2026.04.001_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108563","article-title":"Bile acids inhibit equilibrative adenosine transport to alter adenosine receptor signaling in cholestasis","volume":"301","author":"Joshi","year":"2025","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cld.2026.04.001_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110497","article-title":"P2 purinergic signaling and pruritus","volume":"275","author":"Liu","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cld.2026.04.001_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2023.01.038","article-title":"Adenosine induces IL-31 secretion by T-helper 2 cells: implication for the effect of adenosine on atopic dermatitis and its therapeutic strategy","volume":"645","author":"Kawano","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib23","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2026.04.001_bib26","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.3390\/ijms23116046","article-title":"Molecular basis of bile Acid-FXR-FGF15\/19 signaling axis","volume":"23","author":"Katafuchi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2018-000256","article-title":"Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel","volume":"6","author":"Pate","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.001_bib29","author":"GlaxoSmithKline"},{"issue":"9","key":"10.1016\/j.cld.2026.04.001_bib32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","article-title":"Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Miethke","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"25","key":"10.1016\/j.cld.2026.04.001_bib34","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1016\/j.cell.2024.10.001","article-title":"Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.cld.2026.04.001_bib35","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.autrev.2016.03.019","article-title":"Autotaxin, pruritus and primary biliary cholangitis (PBC)","volume":"15","author":"Sun","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.canlet.2009.04.029","article-title":"Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells","volume":"284","author":"Jansen","year":"2009","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/srep30847","article-title":"Serum autotaxin is a marker of the severity of liver injury and overall survival in patients with cholestatic liver diseases","volume":"6","author":"Wunsch","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.cld.2026.04.001_bib38","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1113\/JP273961","article-title":"Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1\/TRPV1","volume":"595","author":"Kittaka","year":"2017","journal-title":"J Physiol"},{"issue":"15","key":"10.1016\/j.cld.2026.04.001_bib39","doi-asserted-by":"crossref","first-page":"8177","DOI":"10.3390\/ijms25158177","article-title":"Lysophosphatidic acid receptors LPAR5 and LPAR2 inversely control hydroxychloroquine-evoked itch and scratching in mice","volume":"25","author":"Fischer","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib40","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus","volume":"139","author":"Kremer","year":"2010","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2026.04.001_bib41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000440829","article-title":"Pathogenesis and management of pruritus in PBC and PSC","volume":"33","author":"Kremer","year":"2015","journal-title":"Dig Dis"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib42","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions","volume":"56","author":"Kremer","year":"2012","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.cld.2026.04.001_bib43","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cld.2026.04.001_bib44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2026.04.001_bib45","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.14309\/ajg.0000000000003603","article-title":"Long-term efficacy and safety of selective PPAR\u03b4 agonist seladelpar in primary biliary cholangitis: ASSURE interim study results","volume":"121","author":"Levy","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.cld.2026.04.001_bib46","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.04.001_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)00404-0","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","author":"Levy","year":"2025","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102056","article-title":"Selective PPAR\u03b4 agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway","volume":"298","author":"Kouno","year":"2022","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib49","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/501739","article-title":"Regulation of bile acid and cholesterol metabolism by PPARs","volume":"2009","author":"Li","year":"2009","journal-title":"PPAR Res"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib50","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3350\/cmh.2025.0575","article-title":"Association of bile acid composition with synthetic pathways and efficacy of bezafibrate in cholestatic liver disease","volume":"31","author":"Iida","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcpt.13971","article-title":"The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism","volume":"134","author":"Sun","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.cld.2026.04.001_bib52","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jcmgh.2022.07.012","article-title":"Hepatocyte-secreted autotaxin exacerbates nonalcoholic fatty liver disease through autocrine inhibition of the PPAR\u03b1\/FGF21 axis","volume":"14","author":"Qiu","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018932","article-title":"Lysophosphatidic acid activates peroxisome proliferator activated Receptor-\u03b3 in CHO cells that over-express glycerol 3-Phosphate Acyltransferase-1","volume":"6","author":"Stapleton","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2026.04.001_bib54","article-title":"Peroxisome proliferator-activated receptors regulate hepatic immunity and assist in the treatment of primary biliary cholangitis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.001_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.639097","article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib57","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: a new key player in dermatology and beyond","volume":"141","author":"Ba\u011fci","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.cld.2026.04.001_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.15586\/aei.v50i1.521","article-title":"Correlation between interleukin 31 and clinical manifestations in children with atopic dermatitis: an observational study","volume":"50","author":"Duca","year":"2022","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"6","key":"10.1016\/j.cld.2026.04.001_bib60","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1152\/jn.00206.2012","article-title":"Pruriceptive spinothalamic tract neurons: physiological properties and projection targets in the primate","volume":"108","author":"Davidson","year":"2012","journal-title":"J Neurophysiol"},{"issue":"8","key":"10.1016\/j.cld.2026.04.001_bib61","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1152\/jn.00668.2013","article-title":"Characterization of pruriceptive trigeminothalamic tract neurons in rats","volume":"111","author":"Moser","year":"2014","journal-title":"J Neurophysiol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib62","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1038\/s41467-020-16859-5","article-title":"Central circuit mechanisms of itch","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib63","article-title":"The neuroscience of itch in relation to transdiagnostic psychological approaches","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.34","article-title":"Primary biliary cholangitis alters functional connections of the brain\u2019s deep gray matter","volume":"8","author":"Mosher","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib65","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib66","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/MPG.0000000000001385","article-title":"Sertraline as an additional treatment for cholestatic pruritus in children","volume":"64","author":"Th\u00e9baut","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"24","key":"10.1016\/j.cld.2026.04.001_bib67","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.2024.4899","article-title":"Chronic pruritus: a review","volume":"331","author":"Butler","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2026.04.001_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2022.110925","article-title":"Research in the pruritus of cholestasis: genetics, behavioral studies, and physiomimetic interorgan models","volume":"166","author":"Bergasa","year":"2022","journal-title":"Med Hypotheses"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib69","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2007.01.006","article-title":"Endogenous opioid peptides and chronic liver disease: from bedside to bench","volume":"46","author":"Marzioni","year":"2007","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib70","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2026.04.001_bib71","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study","volume":"37","author":"Terg","year":"2002","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib72","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0016-5085(00)70225-3","article-title":"Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis","volume":"118","author":"Jones","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.001_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.641163","article-title":"Endogenous opioid levels do not correlate with itch intensity and therapeutic interventions in hepatic pruritus","volume":"8","author":"D\u00fcll","year":"2021","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib75","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.04.017","article-title":"The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study","volume":"59","author":"Carbone","year":"2013","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2026.04.001_bib76","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/apt.13794","article-title":"The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis","volume":"44","author":"Dyson","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.cld.2026.04.001_bib77","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1007\/s10620-019-06009-3","article-title":"Symptom burden and treatment response in patients with primary biliary cholangitis (PBC)","volume":"65","author":"Kaps","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib78","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cgh.2018.04.047","article-title":"Characteristics and outcomes reported by patients with primary sclerosing cholangitis through an online registry","volume":"17","author":"Kuo","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib79","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/liv.15471","article-title":"Disease burden in primary sclerosing cholangitis in the Netherlands: a long-term follow-up study","volume":"43","author":"van Munster","year":"2023","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib80","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hep.23683","article-title":"The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice","volume":"52","author":"Al-Harthy","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2026.04.001_bib81","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.tins.2025.01.003","article-title":"Defining brain fog across medical conditions","volume":"48","author":"Denno","year":"2025","journal-title":"Trends Neurosci"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib82","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1007\/s10620-020-06502-0","article-title":"Understanding fatigue in primary biliary cholangitis","volume":"66","author":"Phaw","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.cld.2026.04.001_bib83","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cgh.2008.04.013","article-title":"Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis","volume":"6","author":"Hollingsworth","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib84","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.3390\/ijerph19073909","article-title":"Central and peripheral fatigue in physical exercise explained: a narrative review","volume":"19","author":"Tornero-Aguilera","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"10.1016\/j.cld.2026.04.001_bib85","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jhep.2010.05.036","article-title":"Central nervous system dysfunction in primary biliary cirrhosis and its relationship to symptoms","volume":"53","author":"McDonald","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.001_bib86","doi-asserted-by":"crossref","DOI":"10.1177\/2398212818812012","article-title":"Central control of autonomic function","volume":"2","author":"Coote","year":"2018","journal-title":"Brain and Neuroscience Advances"},{"key":"10.1016\/j.cld.2026.04.001_bib87","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jns.2017.04.023","article-title":"Association between autonomic dysfunction and fatigue in Parkinson disease","volume":"377","author":"Chou","year":"2017","journal-title":"J Neurol Sci"},{"issue":"8","key":"10.1016\/j.cld.2026.04.001_bib88","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3390\/jcm9082531","article-title":"Autonomic phenotypes in Chronic Fatigue Syndrome (CFS) are associated with illness severity: a cluster analysis","volume":"9","author":"S\u0142omko","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.meg.0000252629.96043.67","article-title":"Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity","volume":"19","author":"Newton","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2026.04.001_bib90","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/liv.12709","article-title":"Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output","volume":"35","author":"Dyson","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.001_bib91","first-page":"81","article-title":"Autonomic dysfunction in chronic liver disease","volume":"3","author":"Frith","year":"2011","journal-title":"Hepat Med"},{"key":"10.1016\/j.cld.2026.04.001_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101874","article-title":"Structural brain changes in patients with post-COVID fatigue: a prospective observational study","volume":"58","author":"Heine","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib93","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3390\/neurolint14020042","article-title":"Brain structural and functional alterations in multiple sclerosis-related fatigue: a systematic review","volume":"14","author":"Barbi","year":"2022","journal-title":"Neurol Int"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib94","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/1352458517751650","article-title":"Gray matter networks and cognitive impairment in multiple sclerosis","volume":"25","author":"Rimkus","year":"2019","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78768-3","article-title":"Using functional connectivity changes associated with cognitive fatigue to delineate a fatigue network","volume":"10","author":"Wylie","year":"2020","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.cld.2026.04.001_bib96","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1523\/JNEUROSCI.0067-17.2017","article-title":"The human thalamus is an integrative hub for functional brain networks","volume":"37","author":"Hwang","year":"2017","journal-title":"J Neurosci"},{"key":"10.1016\/j.cld.2026.04.001_bib97","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81282","article-title":"Thalamocortical contributions to cognitive task activity","volume":"11","author":"Hwang","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.cld.2026.04.001_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2024.120888","article-title":"Changes in thalamic functional connectivity in Post-Covid patients with and without fatigue","volume":"301","author":"Leitner","year":"2024","journal-title":"Neuroimage"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib99","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1212\/WNL.0b013e31827b910b","article-title":"The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects","volume":"80","author":"Minagar","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.cld.2026.04.001_bib100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fneur.2020.00251","article-title":"The potential role of neurophysiology in the management of multiple sclerosis-related fatigue","volume":"11","author":"Capone","year":"2020","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.cld.2026.04.001_bib101","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/apt.13797","article-title":"Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging","volume":"44","author":"Grover","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211906","article-title":"Primary biliary cholangitis patients exhibit MRI changes in structure and function of interoceptive brain regions","volume":"14","author":"Mosher","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib103","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41467-024-45921-9","article-title":"Organization of reward and movement signals in the basal ganglia and cerebellum","volume":"15","author":"Larry","year":"2024","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib104","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00702-016-1510-0","article-title":"Reward functions of the basal ganglia","volume":"123","author":"Schultz","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/srep21386","article-title":"Basal ganglia correlates of fatigue in young adults","volume":"6","author":"Nakagawa","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib106","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.neuroimage.2007.02.008","article-title":"Effects of motor fatigue on human brain activity, an fMRI study","volume":"35","author":"van Duinen","year":"2007","journal-title":"Neuroimage"},{"key":"10.1016\/j.cld.2026.04.001_bib107","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fneur.2017.00483","article-title":"Cortical substrate of supraspinal fatigue following exhaustive aerobic exercise localizes to a large cluster in the anterior premotor cortex","volume":"8","author":"Herath","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.cld.2026.04.001_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1171253","article-title":"Avenues within the gut-liver-brain axis linking chronic liver disease and symptoms","volume":"17","author":"Nguyen","year":"2023","journal-title":"Front Neurosci"},{"key":"10.1016\/j.cld.2026.04.001_bib109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/7854_2016_37","article-title":"Immune-to-Brain communication pathways in inflammation-associated sickness and depression","volume":"31","author":"D\u2019Mello","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tins.2013.10.003","article-title":"The neuroimmune basis of fatigue","volume":"37","author":"Dantzer","year":"2014","journal-title":"Trends Neurosci"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib111","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jhep.2011.09.014","article-title":"Regulatory T cells suppress sickness behaviour development without altering liver injury in cholestatic mice","volume":"56","author":"Nguyen","year":"2012","journal-title":"J Hepatol"},{"issue":"3\u20134","key":"10.1016\/j.cld.2026.04.001_bib112","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaut.2009.09.010","article-title":"Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis","volume":"33","author":"Barak","year":"2009","journal-title":"J Autoimmun"},{"issue":"16","key":"10.1016\/j.cld.2026.04.001_bib113","doi-asserted-by":"crossref","first-page":"389","DOI":"10.21037\/atm.2019.07.100","article-title":"The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis","volume":"7","author":"Sun","year":"2019","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib114","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/jir.2013.0075","article-title":"Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis","volume":"34","author":"Landi","year":"2014","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00281-009-0154-7","article-title":"The immunobiology of primary sclerosing cholangitis","volume":"31","author":"Aron","year":"2009","journal-title":"Semin Immunopathol"},{"issue":"7","key":"10.1016\/j.cld.2026.04.001_bib116","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1523\/JNEUROSCI.3567-08.2009","article-title":"Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation","volume":"29","author":"D\u2019Mello","year":"2009","journal-title":"J Neurosci"},{"issue":"37","key":"10.1016\/j.cld.2026.04.001_bib117","doi-asserted-by":"crossref","first-page":"14878","DOI":"10.1523\/JNEUROSCI.1329-13.2013","article-title":"P-selectin-mediated monocyte-cerebral endothelium adhesive interactions link peripheral organ inflammation to sickness behaviors","volume":"33","author":"D\u2019Mello","year":"2013","journal-title":"J Neurosci"},{"issue":"30","key":"10.1016\/j.cld.2026.04.001_bib118","doi-asserted-by":"crossref","first-page":"10821","DOI":"10.1523\/JNEUROSCI.0575-15.2015","article-title":"Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain","volume":"35","author":"D\u2019Mello","year":"2015","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.cld.2026.04.001_bib119","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/j.gastro.2017.08.011","article-title":"Interactions between platelets and inflammatory monocytes affect sickness behavior in mice with liver inflammation","volume":"153","author":"D\u2019Mello","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2026.04.001_bib120","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.30099","article-title":"Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial","volume":"70","author":"Khanna","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2026.04.001_bib121","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary biliary cholangitis drug evaluation and regulatory approval: where do we go from here?","volume":"80","author":"Jones","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib122","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2024.04.008","article-title":"Assessment of fatigue and its impact in chronic liver disease","volume":"81","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib123","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000057","article-title":"Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial","volume":"7","author":"Jones","year":"2023","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.cld.2026.04.001_bib124","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3138\/canlivj-2022-0045","article-title":"The feasibility and acceptability of an online mind-body wellness program for patients with primary biliary cholangitis","volume":"6","author":"Watt","year":"2023","journal-title":"Canadian Liver Journal"},{"issue":"12","key":"10.1016\/j.cld.2026.04.001_bib125","article-title":"A home-based exercise programme attenuates fatigue in primary biliary cholangitis: results from the EXCITED clinical trial","volume":"6","author":"Freer","year":"2024","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.cld.2026.04.001_bib126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4254\/wjh.v12.i2.46","article-title":"Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: a systematic review","volume":"12","author":"Noureddin","year":"2020","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.001_bib127","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2006.03223.x","article-title":"An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis","volume":"25","author":"Jones","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2026.04.001_bib128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.mehy.2003.11.044","article-title":"Bupropion for fatigue and as a tumor necrosis factor-\u03b1 lowering agent in primary biliary cirrhosis","volume":"64","author":"Altschuler","year":"2005","journal-title":"Med Hypotheses"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:35:56Z","timestamp":1784763356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1089326126000358"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.001","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Scientific Basis of Cholestatic Liver Disease and Its Symptom Complex","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}